Ticker

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS), (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced the pricing of up to a $4 million best-efforts public offering, with $3 million funded at an initial closing of the offering (the “Initial Closing”) and another $1 million to be funded on the 30th day…

VivoSim Labs (NASDAQ: VIVS - Get Free Report) and Agenus (NASDAQ: AGEN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations. Analyst Ratings This is a summary of recent

ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity

VivoSim Labs, Inc. (NASDAQ: VIVS - Get Free Report) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 32,826 shares, a drop of 62.6% from the February 12th total of 87,870 shares. Based on an average daily volume of 94,910 shares, the days-to-cover ratio

Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim's reach with biopharma innovators seeking human-relevant liver and GI toxicity solutions Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial…